TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Under the Healthcare Common Procedure Coding System (HCPCS), the BRIUMVI J-Code (J2329) will become effective July 1, 2023.
Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “The issuance of a permanent J-Code for BRIUMVI is a significant milestone in our early launch phase. Once in effect, the permanent J-Code will provide a streamlined and efficient reimbursement process, which we believe will facilitate additional patient access. We are encouraged by the early launch of BRIUMVI and look forward to sharing additional details on our first quarter earnings call.”
J-codes are permanent, product specific, reimbursement codes used by commercial insurance plans and government payers for Medicare Part B drugs like BRIUMVI that are administered by a physician. A permanent J-code simplifies the claims submission and documentation process, which in turn streamlines the billing and reimbursement process. The permanent J-code for BRIUMVI is published online on the CMS website here.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.